6,004 Shares in Atrion Co. (ATRI) Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. acquired a new stake in shares of Atrion Co. (NASDAQ:ATRI) in the 3rd quarter, Holdings Channel reports. The firm acquired 6,004 shares of the medical instruments supplier’s stock, valued at approximately $4,172,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Strs Ohio lifted its stake in Atrion by 7.7% during the 2nd quarter. Strs Ohio now owns 1,400 shares of the medical instruments supplier’s stock valued at $839,000 after acquiring an additional 100 shares during the period. Schroder Investment Management Group lifted its stake in Atrion by 11.7% during the 2nd quarter. Schroder Investment Management Group now owns 1,033 shares of the medical instruments supplier’s stock valued at $619,000 after acquiring an additional 108 shares during the period. Aperio Group LLC lifted its stake in Atrion by 8.8% during the 2nd quarter. Aperio Group LLC now owns 1,378 shares of the medical instruments supplier’s stock valued at $826,000 after acquiring an additional 112 shares during the period. Wells Fargo & Company MN lifted its stake in Atrion by 3.6% during the 1st quarter. Wells Fargo & Company MN now owns 3,583 shares of the medical instruments supplier’s stock valued at $2,262,000 after acquiring an additional 123 shares during the period. Finally, Royce & Associates LP lifted its stake in Atrion by 0.5% during the 2nd quarter. Royce & Associates LP now owns 39,227 shares of the medical instruments supplier’s stock valued at $23,513,000 after acquiring an additional 178 shares during the period. Institutional investors and hedge funds own 61.79% of the company’s stock.

NASDAQ:ATRI opened at $682.18 on Friday. The company has a market cap of $1.26 billion, a PE ratio of 37.46 and a beta of 0.56. Atrion Co. has a 1-year low of $516.85 and a 1-year high of $718.11.

Atrion (NASDAQ:ATRI) last posted its earnings results on Tuesday, August 7th. The medical instruments supplier reported $4.70 earnings per share for the quarter. The firm had revenue of $38.85 million during the quarter. Atrion had a net margin of 22.57% and a return on equity of 17.99%.

Separately, BidaskClub lowered shares of Atrion from a “buy” rating to a “hold” rating in a report on Tuesday, August 28th.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Featured Story: Market Capitalization

Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply